Indivior PLC announces new board member

Today, Indivior PLC (LON:INDV), a pharmaceutical company specializing in pharmaceutical preparations with a market capitalization of $2.05 billion, announced the appointment of a new Independent (LON:IOG) Non-Executive Director.

The information, released in a Form 6-K filing with the U.S. Securities and Exchange Commission, was also sent to the London Stock Exchange (LON:LSEG) on February 03, 2025. According to InvestingPro analysis, the company currently trades at an attractive P/E ratio of 9.36 and maintains a GOOD financial health score.

The newly appointed director’s role is to provide independent oversight and constructive challenge to the company’s executive team. This addition to the board is part of Indivior’s commitment to maintaining high standards of corporate governance.

Indivior PLC, with its principal executive office located in North Chesterfield, Virginia, files annual reports under the cover of Form 20-F. The company’s focus on pharmaceutical preparations positions it within the healthcare sector, where corporate governance and the expertise of board members are critical to business success.

This announcement follows the required regulatory procedures for publicly traded companies, ensuring transparency and compliance with international standards. The appointment is effective immediately, and it is expected that the new board member will contribute to Indivior’s strategic direction and governance with their independent perspective.

The company has not disclosed further details about the appointee’s background or previous experience in the press release statement. The appointment comes as Indivior continues to navigate the complex regulatory and competitive landscape of the pharmaceutical industry.

The SEC filing and the announcement to the London Stock Exchange provide the public and investors with the latest governance developments within Indivior PLC. The company’s SEC file number is 001-37835, and the information is based on the press release statement.

In other recent news, Garrett Motion (NASDAQ:GTX) Inc. has made significant strides in its financial performance and capital allocation strategies. The company successfully refinanced its debt, restructuring a $692 million term loan and a $600 million credit line, now increased to $630 million, extending their maturities to 2032 and 2030 respectively. The new financial arrangements offer more favorable terms, reducing interest rates, and improving the company’s debt maturity profile.

Garrett Motion also announced a new capital allocation framework, planning to return 75% or more of its Adjusted Free Cash Flow to shareholders through share repurchases and quarterly cash dividends, beginning in 2025. The company’s Board has approved a share repurchase program, authorizing the buyback of up to $250 million of its common stock throughout 2025.

These recent developments follow Garrett Motion’s strong Q3 2024 results, featuring an adjusted EBITDA margin of 17.4% and $71 million in adjusted free cash flow. The company also secured a letter of intent with SinoTruk for an electric powertrain expected in 2027. Despite a challenging macroeconomic environment, the company projects full-year net sales at $3.45 billion with an adjusted EBITDA of $595 million.

InvestingPro has highlighted Garrett Motion’s aggressive share buyback strategy, as the company has repurchased $438 million in stock since the conversion of its Series A Preferred Stock through Q3 2024. The company also reduced its debt by approximately $400 million during this period. Garrett Motion’s focus remains on R&D investments, particularly in zero-emissions solutions and expanding turbo offerings for hybrid vehicles and industrial applications.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.